BR112018010873A2 - compounds and methods for inhibiting trimethylamine production - Google Patents

compounds and methods for inhibiting trimethylamine production

Info

Publication number
BR112018010873A2
BR112018010873A2 BR112018010873-1A BR112018010873A BR112018010873A2 BR 112018010873 A2 BR112018010873 A2 BR 112018010873A2 BR 112018010873 A BR112018010873 A BR 112018010873A BR 112018010873 A2 BR112018010873 A2 BR 112018010873A2
Authority
BR
Brazil
Prior art keywords
compounds
methods
inhibiting
tma
individual
Prior art date
Application number
BR112018010873-1A
Other languages
Portuguese (pt)
Inventor
Carlos Garcia-Garcia Jose
Leon Stanley Hazen Dr.
August Wos John
Original Assignee
The Procter & Gamble Company
The Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company, The Cleveland Clinic Foundation filed Critical The Procter & Gamble Company
Publication of BR112018010873A2 publication Critical patent/BR112018010873A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a invenção fornece um método para inibir a conversão de colina ou carnitina em trimetilamina (tma) e abaixar tmao em um indivíduo que compreende administrar ao indivíduo uma composição que compreende um composto apresentado na fórmula (i). a invenção também fornece um método para inibir a produção de tma por bactérias que compreende administrar ao indivíduo uma composição que compreende um composto apresentado na fórmula (i), em que o composto é administrado em uma quantidade eficaz para inibir a formação de trimetilamina (tma) a partir de colina ou carnitina no indivíduo.The invention provides a method for inhibiting the conversion of choline or carnitine to trimethylamine (tma) and lowering it in an individual comprising administering to the individual a composition comprising a compound set forth in formula (i). The invention also provides a method for inhibiting bacterial production of tma comprising administering to the subject a composition comprising a compound set forth in formula (i), wherein the compound is administered in an amount effective to inhibit the formation of trimethylamine (tma). ) from choline or carnitine in the individual.

BR112018010873-1A 2015-12-01 2016-12-01 compounds and methods for inhibiting trimethylamine production BR112018010873A2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562261645P 2015-12-01 2015-12-01
US201562261662P 2015-12-01 2015-12-01
US62/261,662 2015-12-01
US62/261,645 2015-12-01
US201662356422P 2016-06-29 2016-06-29
US62/356,422 2016-06-29
PCT/US2016/064299 WO2017095975A1 (en) 2015-12-01 2016-12-01 Compounds and methods for inhibiting production of trimethylamine

Publications (1)

Publication Number Publication Date
BR112018010873A2 true BR112018010873A2 (en) 2019-04-30

Family

ID=57680518

Family Applications (3)

Application Number Title Priority Date Filing Date
BR112018011210A BR112018011210A2 (en) 2015-12-01 2016-12-01 methods to inhibit the conversion of carnitine to trimethylamine (tma)
BR112018010873-1A BR112018010873A2 (en) 2015-12-01 2016-12-01 compounds and methods for inhibiting trimethylamine production
BR112018011216A BR112018011216A2 (en) 2015-12-01 2016-12-01 methods to inhibit the conversion of choline to trimethylamine (tma)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112018011210A BR112018011210A2 (en) 2015-12-01 2016-12-01 methods to inhibit the conversion of carnitine to trimethylamine (tma)

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112018011216A BR112018011216A2 (en) 2015-12-01 2016-12-01 methods to inhibit the conversion of choline to trimethylamine (tma)

Country Status (9)

Country Link
US (3) US10213407B2 (en)
EP (3) EP3383376B1 (en)
CN (3) CN108601753A (en)
AU (4) AU2016365314A1 (en)
BR (3) BR112018011210A2 (en)
CA (3) CA3005760C (en)
PL (1) PL3383376T3 (en)
RU (3) RU2018120183A (en)
WO (3) WO2017095995A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3383376T3 (en) 2015-12-01 2021-10-04 The Procter & Gamble Company Methods for inhibiting conversion of carnitine to trimethylamine (tma)
US11298334B2 (en) * 2016-04-22 2022-04-12 Jc (Wuxi) Company, Inc. Use of isothiocyanate compounds
BR112018076765A2 (en) 2016-06-29 2019-04-02 The Procter & Gamble Company methods to inhibit the conversion of choline to trimethylamine (tma)
CA3066620A1 (en) * 2017-06-08 2018-12-13 Allergyintellect, Inc Vitamin d compounds and methods of using the same
EP4299064A3 (en) * 2017-06-19 2024-03-20 The Cleveland Clinic Foundation Treating disease and promoting weight loss by inhibiting the tma/fmo3/tmao pathway
CN111163761A (en) * 2017-08-14 2020-05-15 普梭梅根公司 Targeted drugs related to trimethylamine and/or trimethylamine-N-oxide
AU2018345749B2 (en) * 2017-10-02 2021-03-11 The Cleveland Clinic Foundation Methods for inhibiting conversion of choline to trimethylamine (TMA)
BR112020006108A2 (en) 2017-10-02 2020-09-24 The Procter & Gamble Company methods to inhibit the conversion of choline to trimethylamine (tma)
BR112020006121B1 (en) 2017-10-02 2022-05-24 The Cleveland Clinic Foundation Methods to inhibit the conversion of choline to trimethylamine (tma)
CN108976485B (en) * 2018-01-22 2020-11-03 内蒙古大学 Gel polysaccharide and rare earth compounded flexible luminescent film and preparation method thereof
EP3746066A4 (en) * 2018-02-01 2023-05-10 The Cleveland Clinic Foundation Disease detection and treatment based on trimethyl-lysine levels
US20200138887A1 (en) 2018-11-06 2020-05-07 The Procter & Gamble Company Methods for inhibiting conversion of choline to trimethylamine (tma)
US11331280B2 (en) 2018-11-06 2022-05-17 The Procter & Gamble Company Methods for inhibiting conversion of choline to trimethylamine (TMA)
CA3121513A1 (en) * 2018-12-06 2020-06-11 Senda Biosciences, Inc. Decarboxylase inhibitors for treating parkinson's disease

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1242863A (en) * 1968-05-10 1971-08-18 Pharmacia As 2,3-DIHYDRO-5H-THIAZOLO[2,3-b]QUINAZOLINES AND PROCESSES FOR THE PREPARATION THEREOF
US4335141A (en) 1979-12-26 1982-06-15 Merck & Co., Inc. 2-Substituted-aminopropene-and propanenitrile antimicrobial and anti-inflammatory agents
US4874788A (en) 1985-10-01 1989-10-17 Ethyl Corporation Quaternary ammonium compounds
US5547677A (en) 1994-05-20 1996-08-20 Novavax, Inc. Antimicrobial oil-in-water emulsions
CA2337428A1 (en) 1998-08-21 2000-03-02 Anne Schuwey Thermal- and photoinitiated radical polymerization in the presence of an addition fragmentation agent
WO2002016366A1 (en) 2000-08-23 2002-02-28 Itoi Textile Co., Ltd Copper or iron chlorophyllin sodium, pulp, aqueous pigment solution, paper yarn and process for producing the same
JP4099012B2 (en) 2002-07-12 2008-06-11 富士フイルム株式会社 Image forming material
JP4798973B2 (en) * 2004-08-04 2011-10-19 丸善製薬株式会社 Antibacterial composition
US20070199890A1 (en) 2006-02-27 2007-08-30 Agion Technologies, Inc. Antimicrobial activated carbon and use thereof
US8859798B2 (en) 2006-07-06 2014-10-14 Rutgers, The State University Of New Jersey Isothiocyanate compounds, pharmaceutical compositions, and uses thereof
EP2081953A2 (en) * 2006-08-17 2009-07-29 The UAB Research Foundation Immunogenic pcpa polypeptides and uses thereof
US9423405B2 (en) 2007-12-05 2016-08-23 The Cleveland Clinic Foundation Trimethylamine compounds as risk predictors of cardiovascular disease
WO2010084661A1 (en) 2009-01-23 2010-07-29 金印株式会社 Composition, food, food material, pharmaceutical preparation, cosmetic and commodity each containing isothiocyanate compound
US10241093B2 (en) 2009-05-28 2019-03-26 The Cleveland Clinic Foundation Trimethylamine-containing compounds for diagnosis and prediction of disease
CA2790371C (en) * 2009-05-28 2020-09-01 The Cleveland Clinic Foundation Trimethylamine-containing compounds for diagnosis and prediction of disease
WO2010140902A1 (en) * 2009-06-02 2010-12-09 Mark Hampton Inhibitors of macrophage migration inhibitory factor
GB0922505D0 (en) * 2009-12-23 2010-02-10 Plant Bioscience Ltd Use
US20120225020A1 (en) 2011-02-24 2012-09-06 Chekmenev Eduard Y Unsaturated choline analogs and chemical synthesis thereof
BR112014031086A2 (en) 2012-06-11 2017-06-27 Cleveland Clinic Found treatment and prevention of cardiovascular disease and thrombosis
US20140271923A1 (en) * 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
CA2963422A1 (en) 2014-10-03 2016-04-07 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Poly(adp-ribose) polymerase 1 inhibitors structurally unrelated to nad
PL3383376T3 (en) 2015-12-01 2021-10-04 The Procter & Gamble Company Methods for inhibiting conversion of carnitine to trimethylamine (tma)
BR112018076765A2 (en) 2016-06-29 2019-04-02 The Procter & Gamble Company methods to inhibit the conversion of choline to trimethylamine (tma)

Also Published As

Publication number Publication date
PL3383376T3 (en) 2021-10-04
WO2017095995A1 (en) 2017-06-08
RU2018120189A (en) 2020-01-10
BR112018011210A2 (en) 2018-11-21
US20170151250A1 (en) 2017-06-01
RU2018116864A (en) 2020-01-09
RU2018120189A3 (en) 2020-01-10
AU2019280094A1 (en) 2020-01-16
EP3383377A1 (en) 2018-10-10
CA3005760C (en) 2019-10-08
EP3383377B1 (en) 2024-04-17
EP3383376A1 (en) 2018-10-10
CA3007081C (en) 2022-03-29
AU2019280094B2 (en) 2021-09-16
EP3383376B1 (en) 2021-05-12
AU2016365316B2 (en) 2019-11-07
CN108601753A (en) 2018-09-28
AU2016365316A1 (en) 2018-06-21
RU2018120183A3 (en) 2020-01-10
US10213407B2 (en) 2019-02-26
US20170151208A1 (en) 2017-06-01
US10780072B2 (en) 2020-09-22
CN108601754A (en) 2018-09-28
EP3383378B1 (en) 2024-04-17
RU2018116864A3 (en) 2020-01-09
AU2016365314A1 (en) 2018-06-21
CN108472267A (en) 2018-08-31
CA3007061C (en) 2021-03-16
CA3005760A1 (en) 2017-06-08
US10786479B2 (en) 2020-09-29
US20170152222A1 (en) 2017-06-01
EP3383378A1 (en) 2018-10-10
AU2016362298A1 (en) 2018-05-31
WO2017095975A1 (en) 2017-06-08
BR112018011216A2 (en) 2018-11-21
CN108472267B (en) 2021-12-24
CA3007061A1 (en) 2017-06-08
RU2018120183A (en) 2020-01-10
CA3007081A1 (en) 2017-06-08
WO2017095993A1 (en) 2017-06-08
AU2016362298B2 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
BR112018010873A2 (en) compounds and methods for inhibiting trimethylamine production
BR112015022340A2 (en) method for treating or preventing a kallikrein-related disease or disorder in a subject, compound, and pharmaceutical composition
BR112018076765A2 (en) methods to inhibit the conversion of choline to trimethylamine (tma)
BR112016005881A2 (en) compound, pharmaceutical composition and use of compound
BR112017004704A2 (en) compound, pharmaceutical composition, and method for treating a disease or disorder in an individual
BR112017006705A2 (en) heparan sulfate biosynthesis inhibitors for treating diseases
BR112016014412A2 (en) SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREOF
BR112017007144A2 (en) valproic acid or a pharmaceutically acceptable salt thereof, compound, pharmaceutical composition, and, compound or composition for use, use, method or composition.
BR112012000968A8 (en) COMPOUND, COMPOSITION AND METHOD FOR INHIBITING A PHOSPHATIDYL INOSITOL-3 KINASE.
BR112012033013A2 (en) plant disease control composition and method of plant disease control
PE20150887A1 (en) SUBSTITUTE BENZENE COMPOUNDS
CR20160478A (en) COMPOSITION OF CONTROL OF PLANT DISEASES AND METHOD TO CONTROL PLANT DISEASES BY APPLICATION
BR112016028476A2 (en) compounds, composition, use of a compound, method for combating harmful fungi and seeds
BR112016022593A2 (en) compositions and methods for modulating complement factor b expression
BR112013004892A2 (en) fluoropolymer-free surface protection composition
AR088983A1 (en) PROCEDURE FOR THE PREPARATION OF REPLACED 5-FLUORO-1H-PIRAZOLOPIRIDINAS
BR112015018847A2 (en) sodium reduced food products
BR112017010440A2 (en) sublingual administration of riluzole
BR112013021566A2 (en) compound of formula, or a pharmaceutically acceptable salt or adduct thereof and method of preventing and / or treating an individual comprising administering to said individual a therapeutically effective amount of a compound of formula
BR112018010140A8 (en) compounds of formula, composition, use of a compound of formula, method for combating phytopathogenic fungi and seed
BR112018006314A2 (en) formula compound, composition, use of formula compound, method of combating phytopathogenic fungi and coated seed
BR112017011921A2 (en) agent for treating hair deformation
BR112017005242A2 (en) compound, pharmaceutical composition, and compound for use.
BR112018005742A2 (en) topical composition, method for surface disinfection, use of the composition and uses of a composition
BR112018010316A2 (en) compounds of formula, composition, use of a compound of formula, method for combating phytopathogenic fungi and seed

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time